Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (327 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

327 publications

Pictilisib (GDC-0941) Chemical Structure

CAS No. 957054-30-7

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 327 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(39):24427-24433

PubMed: 32929011 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )
Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )

Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100016

PubMed: 32984851 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )
Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882967 ( click the link to review the publication )
Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )
Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )
JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )
Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)e13441

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )
Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )
Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )
Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )
Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26384305 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )
PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )
Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )
J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MlTST4lv[XOnIFHzd4F6		NGGzPWEyKGh?	NVzvXlc4TE2VTx?=	NWjodXl[UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDk[Yx1[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[SC5aYToJGlEPTBib3[gNE4xODNizszN	MXyxPFc2PDZ3NB?=
Sf9	MkjOT4lv[XOnIFHzd4F6		NVPrb5JNOSCq	MXnEUXNQ	NUC0ZY5sUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEhzMES3MXIhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	NVTZTFVOOTh5NUS2OVQ>
Sf9	MVfLbY5ie2ViQYPzZZk>		M4\oNlEhcA>?	M4[1OGROW09?	MnrJTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGU2PDVvSzDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB\|IN88US=>	M4f5dVE5PzV2NkW0
Sf9	NHf6UnVMcW6jc3WgRZN{[Xl?		NGnDeJoyKGh?	NEHycWxFVVOR	MmqzTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCzN{DPxE1?	NWrCcVZPOTh5NUS2OVQ>
Sf9	NI\DOWpMcW6jc3WgRZN{[Xl?		NGDUO\|MyKGh?	Mnm2SG1UVw>?	NGHUc2FKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHHsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhi	NITBZYoyQDd3NE[1OC=>
MDA-MB-361	Mn;VSpVv[3Srb36gRZN{[Xl?		MUOyJIg>	M4XXN2ROW09?	M1n4T2lvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvODJ6IN88US=>	MXyxPFc2PDZ3NB?=
PC3	Mn;KSpVv[3Srb36gRZN{[Xl?		NXTxZnl4OiCq	MWPEUXNQ	NF3xT2RKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDQR\|Mh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEO3JO69VQ>?	M37EXFE5PzV2NkW0
U87MG	M4DNRWZ2dmO2aX;uJGF{e2G7		M3W5PFIhcA>?	NXL1VHF4TE2VTx?=	Mn7GTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iVUi3UWch[2WubIOge4l1cCCLQ{WwJI9nKDBwMES2JO69VQ>?	MofQNVg4PTR4NUS=
MDA-MB-361	NWXDWlR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFXicIE6PiCq	MVnEUXNQ	MkLmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHerdHigVGlMO0ODIFW1OFUuUyCvdYTheIlwdiC5aYToJGlEPTBib3[gNE44OiEQvF2=	MVexPFc2PDZ3NB?=
A2780	M{jXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWT3N5BWQTZiaB?=	MlPkSG1UVw>?	NHnDeIxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO\|gxKGOnbHzzJJdqfGhiUFnLN2NCKGGwZDDQWGVPKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlE1KM7:TR?=	NWTJUmN3OTh5NUS2OVQ>
PC3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV7nR2FXQTZiaB?=	NI\KPG9FVVOR	MVLJR\|UxRTBwMkig{txO	M3vBPFE5PzV2NkW0
U87MG	NHzueYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkLjPVYhcA>?	MWLEUXNQ	M3nMPGlEPTB;MD65OUDPxE1?	M4f3eVE5PzV2NkW0
Sf9	MYnLbY5ie2ViQYPzZZk>		M3TzdFMxKG2rbh?=	NEm5eFVFVVOR	MkD1TY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHHtc5VvfCCxZjDBWHAh[2:wc4Xt[YQhf2m2aDDJR\|UxKG:oIECuNFQzKM7:TR?=	MVqyNlU1QDN2Mh?=
RAW 264.7	NF;5eHJMcW6jc3WgRZN{[Xl?		MWq5NEBucW5?	MmXPSG1UVw>?	MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCU1RicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlI6QCEQvF2=	NEi2SGMzOjV2OEO0Ni=>
Sf9	NFv3XlNMcW6jc3WgRZN{[Xl?		M3L2ZVEhcA>?		NX7s[oM2UW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2KndHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPGPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMUeg{txO	NULKfVFTOjN3NEC2OFU>
Sf9	M1LUNmtqdmG\|ZTDBd5NigQ>?		MlvxNUBp		NX\KNVhZUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2SnbIThJIV5eHKnc4Pl[C=>	MXiyN\|U1ODZ2NR?=
Sf9	M1PLbWtqdmG\|ZTDBd5NigQ>?		MVSxJIg>		NVTxSG5{UW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=>	NXftdI1FOjN3NEC2OFU>
Sf9	NGDlbZNMcW6jc3WgRZN{[Xl?		NH73Nm0yKGh?		MVrJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2Wm	NEP2fI8zOzV2ME[0OS=>
SKOV3	M2LTRmtqdmG\|ZTDBd5NigQ>?	MlvoNUDPxE1?	M{nIbFEhcA>?	NGnJZZdFVVOR	MmCzTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdg>?	MkfGNlM{PjB\|NEi=
MCF7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3vNUDPxE1?	NVXvWYhyQTZiaB?=	MXrEUXNQ	NGr2XItIUTVyPUCuNFcxOiEQvF2=	MlPuNlM{PjB\|NEi=
SKOV3	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH3cZB1OSEQvF2=	M{nlc\|k3KGh?	NETBOmVFVVOR	NHG0em1IUTVyPUCuNVQ4PiEQvF2=	M3;jV\|I{OzZyM{S4
PC3	NES0cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVS3NkBp	NWTUd2JrTE2VTx?=	NYnwdVZ{UUN3ME2wMlI5KM7:TR?=	MUiyNVk5OTdzNB?=
MCF7.1	NFz5OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVXRdI9wPzJiaB?=	NUD4OXgzTE2VTx?=	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJGhGWjJiZ3Xu[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1?	MV2yNVk5OTdzNB?=
MCF7-neo/Her2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY[3NkBp	NIny[ppFVVOR	NFvBWIpKSzVyPUCuNlkh\|ryP	NHmzXGEzOzZ4MkmwNy=>
MCF7-neo/Her2	MW\LbY5ie2ViQYPzZZk>				NVjUN5ExUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txO	M4\EflI{PjZ{OUCz
PC3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mk[2O\|IhcA>?	NEHVUZFFVVOR	MWXFR\|UxRTBwM{Sg{txO	NIj4dIwzOTl6NU[zPS=>
MCF7.1	NFnXZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmTZO\|IhcA>?	M3mwdmROW09?	M3j6fWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKG23dHHueEB4cXSqIFXDOVAhd2ZiMD6zPUDPxE1?	MlHWNlE6QDV4M{m=
PC3	M330fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2jhWlczKGh?	M1y3SmROW09?	NH7zbFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDk[YZq[2mnboSgbY4hWFSHTjD3bZRpKEmFNUCgc4YhOC5\|OTFOwG0>	M3S1[\|IxODVyNk[5
MCF7.1	M3vORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUC1V2ttPzJiaB?=	MWLEUXNQ	MnvIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkO0JO69VQ>?	MkOzNlAxPTB4Nkm=
MCF7.1	M134c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGPEbYE4OiCq		M4DzPWVEPTB;MD63NkDPxE1?	MmHlNlA{PDZ4NU[=
NCI-H1975	M3jGU2N6fG:2b4jpZ{BCe3OjeR?=		NXrmZ3VCPzJiaB?=		M4\4UGlEPTB;MD6yO{DPxE1?	NHLZboEzOzB3OUW0OS=>
H460	NIT4PIJEgXSxdH;4bYMhSXO\|YYm=		Ml32O\|IhcA>?		MoPuTWM2OD1yLki3JO69VQ>?	M3vLRlI{ODV7NUS1
HT-29	MXvDfZRwfG:6aXOgRZN{[Xl?		Mnf1O\|IhcA>?		MUjJR\|UxRTBwNk[g{txO	MYKyN\|A2QTV2NR?=
HepG2	NHTDbnpEgXSxdH;4bYMhSXO\|YYm=		M{fKXVczKGh?		M{[yWWlEPTB;MTFOwG0>	M{\4TFI{ODV7NUS1
SGC7901	NELufZpEgXSxdH;4bYMhSXO\|YYm=		NYrqZpU4PzJiaB?=		NHLKXI1KSzVyPUGuPEDPxE1?	MonmNlMxPTl3NEW=
NCI-H226	MVnDfZRwfG:6aXOgRZN{[Xl?		MWq3NkBp		MV3JR\|UxRTJwOTFOwG0>	NGewWY8zOzB3OUW0OS=>
A549	MYHDfZRwfG:6aXOgRZN{[Xl?		Ml3CO\|IhcA>?		NHmzdJhKSzVyPU[uPUDPxE1?	NUnKTlFCOjNyNUm1OFU>
U87MG	NEH4UWlEgXSxdH;4bYMhSXO\|YYm=		MoDJO\|IhcA>?		M2TwdWlEPTB;Nz63O{DPxE1?	NV;2fY9sOjNyNUm1OFU>
HBC4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13hZoxw\0eLNUC9MVYvODNiTR?=	M3juTVIzOzN4MkS2
BSY1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPndGtjdG:pR1m1NF0uPi57MDDN	NYHlWW1oOjJ\|M{[yOFY>
HBC5	NIq1Z2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYmxZ4JxdG:pR1m1NF0uPi54MDDN	MYmyNlM{PjJ2Nh?=
MCF7	M{\1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHEXG5OdG:pR1m1NF0uPy5\|MzDN	M3zEZ\|IzOzN4MkS2
MDA-MB-231	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mle0cI9oT0l3ME2tOU41PiCP	NF\PWoczOjN\|NkK0Oi=>
U251	NITodlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LTNIxw\0eLNUC9MVUvPTBiTR?=	NWjZdm1POjJ\|M{[yOFY>
SF268	NXzGc5JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjBV3hPdG:pR1m1NF0uPS5\|OTDN	MmPXNlI{OzZ{NE[=
SF295	NUnz[Gp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3wTHhtd2eJSUWwQU03NjN5IF2=	MkD2NlI{OzZ{NE[=
SF539	NEmxbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfsc4dIUTVyPT22MlUxKE1?	NYDIV\|I{OjJ\|M{[yOFY>
SNB75	NIOxRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4q5W4xw\0eLNUC9MVcvOTBiTR?=	M{PoWVIzOzN4MkS2
SNB78	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHTbGVtdG:pR1m1NF0uPi53MjDN	M{SxdVIzOzN4MkS2
HCC2998	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HxUYxw\0eLNUC9MVYvOjliTR?=	NV3ZW4g6OjJ\|M{[yOFY>
KM12	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvGRnVtd2eJSUWwQU02Njd4IF2=	NFK3VpozOjN\|NkK0Oi=>
HT-29	NXPj[2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3sc4dIUTVyPT22MlMxKE1?	MkTRNlI{OzZ{NE[=
HCT15	NETIV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;KcI9oT0l3ME2tOk4yOiCP	MnHONlI{OzZ{NE[=
HCT116	M4T4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT0S4dtd2eJSUWwQU02Njh5IF2=	NWPsN5U2OjJ\|M{[yOFY>
NCI-H23	NYW5PHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYezbFJ5dG:pR1m1NF0uPS55MzDN	Mm\wNlI{OzZ{NE[=
NCI-H226	M{nCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYj5SVZkdG:pR1m1NF0uPi5{MTDN	NGrrbmkzOjN\|NkK0Oi=>
NCI-H522	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli2cI9oT0l3ME2tOk42QCCP	NUnZU3FLOjJ\|M{[yOFY>
NCI-H483	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHsc4dIUTVyPT22MlU3KE1?	MofhNlI{OzZ{NE[=
A549	MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS3dYRtd2eJSUWwQU03NjF3IF2=	M4nVe\|IzOzN4MkS2
DMS273	M2DObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTFcI9oT0l3ME2tOk41OyCP	M{PzSVIzOzN4MkS2
DMS114	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjqZmNtd2eJSUWwQU02Njl{IF2=	M4PYXlIzOzN4MkS2
LOXIMVI	M1\oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHsc4dIUTVyPT22MlI6KE1?	Ml3HNlI{OzZ{NE[=
OVCAR3	NX6x[pdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X1XYxw\0eLNUC9MVYvPzFiTR?=	MonpNlI{OzZ{NE[=
OVCAR4	M2L5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\Yb4xw\0eLNUC9MVUvPzZiTR?=	M4G3XlIzOzN4MkS2
OVCAR5	NEnkU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEmyR4Vtd2eJSUWwQU03NjJ4IF2=	NVfHSJJlOjJ\|M{[yOFY>
OVCAR8	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSwcYdndG:pR1m1NF0uPS55MzDN	NHHtNIgzOjN\|NkK0Oi=>
SKOV3	NEDk[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDsc4dIUTVyPT22MlUzKE1?	NIfPPI0zOjN\|NkK0Oi=>
RXF631L	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\pUIxw\0eLNUC9MVYvQDhiTR?=	MWeyNlM{PjJ2Nh?=
ACHN	NF;hSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vXSIxw\0eLNUC9MVYvODdiTR?=	NW\lO3M4OjJ\|M{[yOFY>
St-4	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjweJpSdG:pR1m1NF0uPS53NjDN	MoDDNlI{OzZ{NE[=
MKN1	M2f1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4O0fIxw\0eLNUC9MVcvODhiTR?=	NYG3U4d4OjJ\|M{[yOFY>
MKN7	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\2cYxw\0eLNUC9MVYvPTBiTR?=	MVmyNlM{PjJ2Nh?=
MKN28	M2LOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHsc4dIUTVyPT21MlUzKE1?	Ml;1NlI{OzZ{NE[=
MKN45	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXsc4dIUTVyPT22MlU2KE1?	M2T1fFIzOzN4MkS2
MKN74	NV\1bGtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\sc4dIUTVyPT22MlAzKE1?	NWewRmtUOjJ\|M{[yOFY>
DU145	NH\HSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jOVYxw\0eLNUC9MVUvQDViTR?=	NX\aUFRmOjJ\|M{[yOFY>
PC3	NWXpNYFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPFUHBtd2eJSUWwQU03NjZ4IF2=	NV;y[IszOjJ\|M{[yOFY>
ES5	NYnUbHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlT5TWM2OD13MD6yNUBvVQ>?	NFmzR3hUSU6JRWK=
HH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFS2dYlKSzVyPUGxNU4xQCCwTR?=	MkHEV2FPT0WU
MHH-PREB-1	NV;LblBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfjbowzUUN3ME2xNVQvOyCwTR?=	MV\TRW5ITVJ?
NCI-H1770	NHXxNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnK1TWM2OD1zMkOuPFYhdk1?	Mo\kV2FPT0WU
HuO9	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\3OWZlUUN3ME2yNFYvODJibl2=	NGWyUWNUSU6JRWK=
HAL-01	NED0Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jDfmlEPTB;MkC2Mlc{KG6P	MV;TRW5ITVJ?
NOS-1	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3lcHdKSzVyPUKxNU45OiCwTR?=	NUfiT5ZNW0GQR1XS
HGC-27	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfJTWM2OD1{MUKuOVchdk1?	MlLsV2FPT0WU
NB69	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWj2b3Y5UUN3ME2yOFUvOjdibl2=	NWP1VGRtW0GQR1XS
RS4-11	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXW2XFVnUUN3ME2yOlEvPzZibl2=	NFGzZ2VUSU6JRWK=
DOK	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTNyMT63JI5O	NFfsS5dUSU6JRWK=
LB2241-RCC	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rR[2lEPTB;M{CzMlg1KG6P	NXzodnVoW0GQR1XS
NCI-H1623	NH3l[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K5XGlEPTB;M{C0MlA5KG6P	MmrzV2FPT0WU
YH-13	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjYTWM2OD1\|MESuN\|Ihdk1?	MkDGV2FPT0WU
BPH-1	NHXQ[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mni5TWM2OD1\|MUSgcm0>	MmDJV2FPT0WU
AN3-CA	NFz6T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\URnNKSzVyPUO0NE4{PyCwTR?=	NGTDeolUSU6JRWK=
ES7	M1naTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTN2MT65PUBvVQ>?	NVPxNnJMW0GQR1XS
MDA-MB-175-VII	NWCyZ\|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTN3Mj65NkBvVQ>?	MoLJV2FPT0WU
GAMG	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTN5MD64OUBvVQ>?	NFTlN\|dUSU6JRWK=
CHL-1	NELZXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFi1PGtKSzVyPUO3PE43PSCwTR?=	MULTRW5ITVJ?
NB7	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHBTVZKSzVyPUO4PU45OyCwTR?=	MVTTRW5ITVJ?
MFE-280	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTRzOD6yJI5O	M{nTOnNCVkeHUh?=
HL-60	NWXYWHlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTR{NT63OUBvVQ>?	NYrJZnlmW0GQR1XS
GCIY	NFTaSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfEUXp3UUN3ME20N\|MvQCCwTR?=	M1X6bnNCVkeHUh?=
MDA-MB-361	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnywTWM2OD12M{muNVMhdk1?	MWrTRW5ITVJ?
LXF-289	M2TPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTR2OD6yO{BvVQ>?	NFuzU3ZUSU6JRWK=
NBsusSR	M{XoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vocmlEPTB;NEi4Mlg2KG6P	Ml\aV2FPT0WU
KU-19-19	NUTyeZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTVzNj6wO{BvVQ>?	NFW3VmpUSU6JRWK=
A204	NELZeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mki0TWM2OD13MkKuN\|Mhdk1?	NVXvO4ViW0GQR1XS
LB1047-RCC	NUnrdGFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXWTWM2OD13MkKuPVMhdk1?	M3rWZXNCVkeHUh?=
COLO-684	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\GTWM2OD13MkOuNVEhdk1?	MkXCV2FPT0WU
PA-1	NHnRNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTV\|Mj60NUBvVQ>?	NWjaOnJkW0GQR1XS
MG-63	NEjGc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\RSoVKSzVyPUW0NU4yOSCwTR?=	MmH3V2FPT0WU
BHT-101	NY\wNVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4ntVGlEPTB;NUS0Mlk1KG6P	MkTkV2FPT0WU
NKM-1	M1LhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjXZWJKSzVyPUW5N{4xQSCwTR?=	NXizRWg3W0GQR1XS
T47D	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nteGlEPTB;NUm3MlU3KG6P	M2TmWnNCVkeHUh?=
MOLT-4	NGjz[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjvTWM2OD14MkOuOlIhdk1?	NVXPUZRtW0GQR1XS
IGROV-1	NXvhfZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGn4b2tKSzVyPU[zOE4{OSCwTR?=	M4\tOnNCVkeHUh?=
ES4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXUTWM2OD14M{muOVQhdk1?	NYDCUGJyW0GQR1XS
HuO-3N1	M{C2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\YXmlEPTB;NkSyMlM5KG6P	MoC0V2FPT0WU
NEC8	M1zKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DZXGlEPTB;NkWzMlU4KG6P	M3LYRnNCVkeHUh?=
HO-1-N-1	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoX0TWM2OD14NUmuNVchdk1?	MnznV2FPT0WU
EPCL-272H	NF[4OIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPIbJBmUUN3ME22PFcvOjFibl2=	NHezR5RUSU6JRWK=
D-263MG	M4HsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PwOGlEPTB;N{G4MlEhdk1?	Mn;RV2FPT0WU
MV-4-11	NWO2ZoN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlOwTWM2OD15MkSuN\|Ehdk1?	M4LNenNCVkeHUh?=
SK-NEP-1	M{GyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrieGNFUUN3ME23NlUvQTRibl2=	NV7lNWZPW0GQR1XS
SW872	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES2blBKSzVyPUeyO{45QSCwTR?=	MnG2V2FPT0WU
P30-OHK	M1fKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\IemlEPTB;N{OwMlcyKG6P	M1f6fHNCVkeHUh?=
OMC-1	M37Jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIraT4NKSzVyPUe1NU4xQSCwTR?=	NYDWV5E6W0GQR1XS
LoVo	NWXDOFdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;hfFhKSzVyPUe3O{46KG6P	NGD6VYJUSU6JRWK=
LNCaP-Clone-FGC	NWWyUZdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn2TpBVUUN3ME23PVYvOzRibl2=	MUHTRW5ITVJ?
L-363	M3rjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1WzVGlEPTB;N{m4MlQzKG6P	NVHqUnBuW0GQR1XS
ES8	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvES5ZsUUN3ME24NVAvPTJibl2=	NILhPYxUSU6JRWK=
697	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTh\|MT61OUBvVQ>?	M2mzbXNCVkeHUh?=
HSC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[wTWM2OD16M{muOVQhdk1?	MUHTRW5ITVJ?
H4	NFPaTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\MTWM2OD16NUCuPFUhdk1?	NUXG[WlNW0GQR1XS
QIMR-WIL	NUe2PItsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK0VlJnUUN3ME24OlUvOiCwTR?=	NH[1V\|RUSU6JRWK=
OAW-42	NWXFPHA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHlcndmUUN3ME24O\|IvOTlibl2=	MYXTRW5ITVJ?
MCF7	M1\uWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\pZ5dKSzVyPUi5PE42QSCwTR?=	NWrxe\|N[W0GQR1XS
SCC-25	NEPobG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojBTWM2OD17MUSuNVkhdk1?	MkDWV2FPT0WU
NCI-H1563	M3;ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnrTWM2OD17MUWuPVkhdk1?	MVzTRW5ITVJ?
OVCAR-5	M4TLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;0T2lEPTB;OUSwMlE4KG6P	M{HEUHNCVkeHUh?=
HDLM-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTl2OT6yJI5O	NGH2[XNUSU6JRWK=
NB5	NGr5N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrWTWM2OD17NU[uOkBvVQ>?	NFznepJUSU6JRWK=
NCI-H292	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTl5ND6zNkBvVQ>?	MVjTRW5ITVJ?
A101D	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYf3fJRUUUN3ME25PVAvOTlibl2=	NWPtN4E2W0GQR1XS
NCI-H1648	NUfsU3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TSemlEPTB;OUm4MlUyKG6P	MlvWV2FPT0WU
EKVX	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPNNYpKSzVyPUGuNFEzQSEQvF2=	M4Dre3NCVkeHUh?=
SW1710	NVLMd3dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXO5fVFoUUN3ME2xMlA1OjN\|IN88US=>	MmjsV2FPT0WU
WM-115	M3HLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFwME[2OVYh\|ryP	Ml;SV2FPT0WU
CAL-54	NVTkSYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TINWlEPTB;MT6wO\|A5OSEQvF2=	MlvHV2FPT0WU
TGBC24TKB	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTFwMEiwOFUh\|ryP	M3L1eHNCVkeHUh?=
NCI-H520	NW\uO4N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPpbZBKSzVyPUGuNFg6PjdizszN	NWH1T2FuW0GQR1XS
D-423MG	M2nUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnMdnBKSzVyPUGuNFk6PjJizszN	NHOwbm5USU6JRWK=
BFTC-905	Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjTWGVKSzVyPUGuNVM1PDlizszN	NWHiSVJzW0GQR1XS
HT	M1ruWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe4XZhKSzVyPUGuNVM1PzhizszN	MoLyV2FPT0WU
CTB-1	NV;wbmt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTFwMUSyPVMh\|ryP	M3TLfnNCVkeHUh?=
Hs-578-T	NHzBXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFwMUm1OlUh\|ryP	MnnuV2FPT0WU
HuH-7	NX3FemxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLvTWM2OD1zLkKwPVQ6KM7:TR?=	NUjNfGs2W0GQR1XS
LB996-RCC	NHu5UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTXS3VUUUN3ME2xMlIzOTd5IN88US=>	MlX0V2FPT0WU
KYSE-270	M4HNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HYd2lEPTB;MT6yPVc{PCEQvF2=	M3L1b3NCVkeHUh?=
A4-Fuk	NEfBO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFX0NGVKSzVyPUGuNlk6QTNizszN	MoDvV2FPT0WU
A498	M3zEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTFwM{C0O\|Qh\|ryP	M2ezOnNCVkeHUh?=
SK-MEL-1	M4XCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPFTWM2OD1zLkOwOlc6KM7:TR?=	NULNPGRCW0GQR1XS
AU565	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHCTWM2OD1zLkOxPFY{KM7:TR?=	M2nIbXNCVkeHUh?=
Saos-2	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHX3RZFKSzVyPUGuN\|MzODVizszN	Mmi1V2FPT0WU
A549	NIG0W4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTQdYtIUUN3ME2xMlM6QTdizszN	NF3GRmtUSU6JRWK=
BFTC-909	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLUeGxpUUN3ME2xMlQ{OzB3IN88US=>	NF3QVVNUSU6JRWK=
MDA-MB-415	MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzQTWM2OD1zLkS4OlkzKM7:TR?=	NWX2PYdFW0GQR1XS
639-V	NUK0[HRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\RTWZKSzVyPUGuOVAzPDVizszN	NEHqOIdUSU6JRWK=
A704	M3jxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr1c3NKSzVyPUGuOVA4QDVizszN	MVvTRW5ITVJ?
PANC-03-27	M1;CWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwNUG0NFgh\|ryP	MlPIV2FPT0WU
SK-MEL-28	M2PzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[xbWlEPTB;MT61OlA5PSEQvF2=	MlXGV2FPT0WU
Ramos-2G6-4C10	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTFwNkC3OFYh\|ryP	MYrTRW5ITVJ?
HuP-T4	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTFwNkC3O\|gh\|ryP	NXPyWXlrW0GQR1XS
VA-ES-BJ	NXPFc4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH3OIdKSzVyPUGuOlEzPyEQvF2=	NGrWSWtUSU6JRWK=
EFM-19	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzhTWM2OD1zLk[xPFEh\|ryP	MknuV2FPT0WU
G-401	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrVT5FYUUN3ME2xMlYzOTZ2IN88US=>	MUXTRW5ITVJ?
D-566MG	NHXYXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnuTWM2OD1zLk[yOVMh\|ryP	NIjEdXJUSU6JRWK=
JVM-3	M4fETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnlTWM2OD1zLk[0PFc2KM7:TR?=	Mlq1V2FPT0WU
TK10	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWe1PWgyUUN3ME2xMlY4ODh\|IN88US=>	NX7qTm9wW0GQR1XS
BT-20	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLHTWM2OD1zLk[4PVAzKM7:TR?=	MVnTRW5ITVJ?
EGI-1	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWX5eFVPUUN3ME2xMlg1PzBzIN88US=>	NEPxfmJUSU6JRWK=
EW-16	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTFwOEWxPFIh\|ryP	M{XUWHNCVkeHUh?=
NCI-H2228	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrCRolKSzVyPUGuPFUzODNizszN	MWXTRW5ITVJ?
BB49-HNC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULy[nM4UUN3ME2xMlg5Pjl{IN88US=>	Mn7JV2FPT0WU
G-402	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jMO2lEPTB;MT64PVc6PyEQvF2=	MYTTRW5ITVJ?
NCI-H526	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTFwOUGzPUDPxE1?	NILtbZdUSU6JRWK=
ME-180	NHj0W\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXQTWM2OD1zLkmzOFc4KM7:TR?=	MmnwV2FPT0WU
PFSK-1	M2GyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwOUS0OVgh\|ryP	NH7hUo9USU6JRWK=
TYK-nu	M4rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTFwOUW4NlMh\|ryP	MULTRW5ITVJ?
HOS	M2TP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvCPYJKSzVyPUGuPVc6PDhizszN	MmXiV2FPT0WU
T98G	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4mwcmlEPTB;MT65PVAxPiEQvF2=	NGTQTZdUSU6JRWK=
SK-MES-1	NF7wc\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PQSmlEPTB;Mj6wNVM{OiEQvF2=	M3j0WXNCVkeHUh?=
SNB75	M1\JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwMEG1OFEh\|ryP	M{XDSXNCVkeHUh?=
LAMA-84	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7SN4JZUUN3ME2yMlAzPjh7IN88US=>	M2TTRXNCVkeHUh?=
CAL-39	M2jhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHv6WWdKSzVyPUKuNFMzQCEQvF2=	MVfTRW5ITVJ?
LOXIMVI	NE\mPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSwTWM2OD1{LkC0NFg1KM7:TR?=	NYezd\|BtW0GQR1XS
NH-12	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJwMEW0NlQh\|ryP	NFnt[\|lUSU6JRWK=
NCI-H1048	NULFWXFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETtSWNKSzVyPUKuNVA2OiEQvF2=	NFPT[W1USU6JRWK=
KS-1	M{PqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwMUGwNFEh\|ryP	NFH4R2RUSU6JRWK=
NCI-N87	M2XqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTpZ5JKSzVyPUKuNVM{QDRizszN	MoDkV2FPT0WU
CHP-212	NF;RXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3zRYZzUUN3ME2yMlE5PDR{IN88US=>	MWXTRW5ITVJ?
HCC1419	NF3ZWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj6TJp3UUN3ME2yMlIyOTF3IN88US=>	M17mbnNCVkeHUh?=
ES1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrOTWM2OD1{LkKxN\|I3KM7:TR?=	NYm2bVVrW0GQR1XS
NCI-H2030	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[wTWM2OD1{LkK0NVI{KM7:TR?=	MXHTRW5ITVJ?
EW-22	NUTkU41vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLJO\|YxUUN3ME2yMlI2ODZ5IN88US=>	NGnJOHNUSU6JRWK=
A431	NI[3b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3riemlEPTB;Mj6yO\|M2PCEQvF2=	NHLZe3JUSU6JRWK=
SF126	M{G4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJwM{C2NlUh\|ryP	M{fSeHNCVkeHUh?=
SF295	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XNVWlEPTB;Mj6zNVUzPCEQvF2=	NUHmU\|FZW0GQR1XS
D-502MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Lu[GlEPTB;Mj6zNlQ3OSEQvF2=	MlzxV2FPT0WU
HCC2157	M4n4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3O4ZWlEPTB;Mj6zNlkzPyEQvF2=	NHXpR5FUSU6JRWK=
D-283MED	M2nUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HC[WlEPTB;Mj6zOVkzPiEQvF2=	Mn7EV2FPT0WU
SNU-423	NXjtco4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{e5O2lEPTB;Mj60NFE4OSEQvF2=	M{LwPXNCVkeHUh?=
SK-LU-1	NIrwcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Lj[mlEPTB;Mj60OFU5PiEQvF2=	Mn72V2FPT0WU
22RV1	NWGyWGNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fMWmlEPTB;Mj60OVYyPyEQvF2=	NYPDUZZ6W0GQR1XS
SW1088	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLaTWM2OD1{LkS5NlE{KM7:TR?=	MUDTRW5ITVJ?
HT-3	Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfmdVNKSzVyPUKuOFkzPTlizszN	MXrTRW5ITVJ?
NCI-H1666	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJwNUGxNFQh\|ryP	MkjJV2FPT0WU
EM-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrzZYFEUUN3ME2yMlUyOTZ7IN88US=>	M2jwb3NCVkeHUh?=
SNU-449	M2Gxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJwNUewNVQh\|ryP	NXnIZ\|V{W0GQR1XS
786-0	M2\BfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PKXGlEPTB;Mj61PVI{QCEQvF2=	Mkm1V2FPT0WU
SKG-IIIa	NVKwR5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4D3S2lEPTB;Mj62OVk{QSEQvF2=	NXHsN2RXW0GQR1XS
MEL-HO	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIn6UohKSzVyPUKuOlc3OzRizszN	NX3JdopnW0GQR1XS
LCLC-97TM1	NXXIb4FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3u0[WlEPTB;Mj62PVI3PyEQvF2=	NGnD[ohUSU6JRWK=
MKN7	NGnjfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjjZ3BKSzVyPUKuO\|A4PTRizszN	MXnTRW5ITVJ?
5637	MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJwN{GwN\|Uh\|ryP	NVmyVolwW0GQR1XS
HOP-92	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rSTWlEPTB;Mj63OFcyPyEQvF2=	MUnTRW5ITVJ?
MDA-MB-157	NHT1V3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NISwZWNKSzVyPUKuPFIxOjNizszN	MlfjV2FPT0WU
NB12	M2DoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3qzPWlEPTB;Mj64OFkyPCEQvF2=	Mlf5V2FPT0WU
DMS-273	NInje2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{WxRWlEPTB;Mj64OlQ4KM7:TR?=	NU\qVlBNW0GQR1XS
HCC70	NIrFSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJwOE[1PFkh\|ryP	MkG5V2FPT0WU
YKG-1	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLobWpzUUN3ME2zMlA{Pzh5IN88US=>	NVTkRYRqW0GQR1XS
NCI-H28	NYmy[IdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTNwMEWyPVEh\|ryP	NGG0b5BUSU6JRWK=
HN	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPEOGFKSzVyPUOuNFY3OzZizszN	MUXTRW5ITVJ?
HT-1080	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTNwMEi2NFYh\|ryP	NEjQXXVUSU6JRWK=
HPAF-II	M1HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTNwMUCwOlgh\|ryP	MV\TRW5ITVJ?
U-2-OS	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP1NIt7UUN3ME2zMlE{Pzh{IN88US=>	M2jPeXNCVkeHUh?=
SNU-387	M{HOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYj1Uo0xUUN3ME2zMlE3OzZ2IN88US=>	MVPTRW5ITVJ?
Becker	NUTJNVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTYTWM2OD1\|LkG2PFA5KM7:TR?=	NWfqUWtoW0GQR1XS
BHY	NYfRfoNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vMeWlEPTB;Mz6yOVU4OSEQvF2=	MVHTRW5ITVJ?
HTC-C3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX65[m5sUUN3ME2zMlI6OzV{IN88US=>	MmLTV2FPT0WU
M14	NW\u[GtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXOTWM2OD1\|LkOwOlY{KM7:TR?=	MnHaV2FPT0WU
COR-L23	MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTQcmlpUUN3ME2zMlM4Ojd7IN88US=>	NEPIUI5USU6JRWK=
C32	NFH4[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFT0WotKSzVyPUOuOFE2ODhizszN	NImxcm1USU6JRWK=
Mewo	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrUZ21KSzVyPUOuOFIyQDJizszN	M2LyRnNCVkeHUh?=
TE-8	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHP5[4pKSzVyPUOuOFgzPTlizszN	MXHTRW5ITVJ?
RPMI-2650	NYj3V3dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXITWM2OD1\|Lk[wOlM4KM7:TR?=	MYfTRW5ITVJ?
AGS	M{TmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTNwNkK0OlQh\|ryP	NUPie3E5W0GQR1XS
MZ2-MEL	NXrKR2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nVR2lEPTB;Mz62OlE{QCEQvF2=	MkTrV2FPT0WU
Calu-3	NIDUTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTNwN{GyPFch\|ryP	MorWV2FPT0WU
SJSA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fSXGlEPTB;Mz63NVMyPSEQvF2=	NH76e3RUSU6JRWK=
SW962	NYr2O3FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDJNZhRUUN3ME2zMlczPjN4IN88US=>	NYPQ[FBDW0GQR1XS
PC-14	NELOdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTNwN{OyNlIh\|ryP	NGDNdmlUSU6JRWK=
SW1573	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTNwN{WzOFgh\|ryP	MXjTRW5ITVJ?
769-P	M4HpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofuTWM2OD1\|LkiyO\|Q{KM7:TR?=	MnjtV2FPT0WU
KNS-62	M1LadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHjVIpNUUN3ME2zMlkzOzN6IN88US=>	NYnUXY1qW0GQR1XS
NCI-H747	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\1TWM2OD12LkC1OlM5KM7:TR?=	NIXTb3lUSU6JRWK=
LN-405	M{XyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlj6TWM2OD12LkG1O\|I5KM7:TR?=	M1K0SnNCVkeHUh?=
OVCAR-8	M{[z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTuO\|dRUUN3ME20MlIzPTR\|IN88US=>	NX3NZWVHW0GQR1XS
DMS-114	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TuV2lEPTB;ND6yN\|g6OSEQvF2=	NEfxdHpUSU6JRWK=
NCI-H2126	M1voSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MomyTWM2OD12LkK0OVU5KM7:TR?=	M13lWHNCVkeHUh?=
TCCSUP	NYXM[WVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKwZ3ptUUN3ME20MlI1Pzh6IN88US=>	NYXWZZBtW0GQR1XS
SK-N-FI	NFrqbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj6N4dsUUN3ME20MlI2OzN{IN88US=>	NUfrZldtW0GQR1XS
HCE-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTRwMkexPVch\|ryP	NEDDVItUSU6JRWK=
DK-MG	M1\5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nYdWlEPTB;ND6zNFM6KM7:TR?=	NYrEcnQ2W0GQR1XS
RO82-W-1	M2nwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLOSnZYUUN3ME20MlMzPTh2IN88US=>	MWjTRW5ITVJ?
A2780	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7STWM2OD12LkO2OlgzKM7:TR?=	M2S5VHNCVkeHUh?=
ETK-1	NFLrcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTRwM{ewOVIh\|ryP	Mm\1V2FPT0WU
FADU	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIOxN2VKSzVyPUSuN\|c1PjdizszN	NIPBXZhUSU6JRWK=
CAL-12T	M1XW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHFXop6UUN3ME20MlQyPDF\|IN88US=>	NHXodnJUSU6JRWK=
647-V	NFvXOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjoPHdKSzVyPUSuOFQxOjJizszN	NF30N5lUSU6JRWK=
TGBC1TKB	NES4[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[0NnBJUUN3ME20MlQ2OTF\|IN88US=>	NYnK[2h{W0GQR1XS
LU-99A	NFe1dY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCwTWM2OD12LkS2NFYh\|ryP	NX3hTFg6W0GQR1XS
CAL-33	NETMUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfTTWM2OD12LkWyOFU3KM7:TR?=	M4m1bXNCVkeHUh?=
LU-134-A	NF24fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXxdG1KSzVyPUSuOVI4PDVizszN	M{\TcnNCVkeHUh?=
NCI-H1355	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTRwNUWxOFYh\|ryP	NYLR[op4W0GQR1XS
RPMI-7951	M1zlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTRwNUewNFIh\|ryP	Mn\WV2FPT0WU
TE-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTRwNk[xOFMh\|ryP	MYrTRW5ITVJ?
OE33	NUntdoF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTRwN{C1NVEh\|ryP	M4P6enNCVkeHUh?=
CAL-51	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVryUFRkUUN3ME20MlcyODh{IN88US=>	MW\TRW5ITVJ?
SW1783	NUnRd5B{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DXfGlEPTB;ND63OVMxQCEQvF2=	MYTTRW5ITVJ?
BT-474	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTRwN{[zPFQh\|ryP	NI\O[\|VUSU6JRWK=
KYSE-520	NV\wXmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUS1N4FNUUN3ME20Mlg4Ozl{IN88US=>	MXHTRW5ITVJ?
8-MG-BA	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTRwOEi1OVch\|ryP	NFH3RWRUSU6JRWK=
IA-LM	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTRwOUm0N\|Uh\|ryP	MXjTRW5ITVJ?
SW954	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M374emlEPTB;ND65PVQ1OyEQvF2=	NFvvTIRUSU6JRWK=
RPMI-8226	M2LKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;LbZRKSzVyPUWuNFU1PjFizszN	NWTUPG06W0GQR1XS
MKN1	NYPM[nNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3xdXVKSzVyPUWuNFc6OjdizszN	NWTYOHI5W0GQR1XS
A375	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUKzVHNNUUN3ME21MlA6OjV4IN88US=>	Ml3RV2FPT0WU
8305C	NYXhOmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTVwMEm4PFch\|ryP	NUK3Zm5CW0GQR1XS
CAL-62	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2e3SmlEPTB;NT6xPFI2QSEQvF2=	NGP3RplUSU6JRWK=
NB10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLPTWM2OD13LkKyO\|Q1KM7:TR?=	MVjTRW5ITVJ?
OC-314	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEH2SIlKSzVyPUWuN\|c1PDRizszN	MnrrV2FPT0WU
PSN1	M{S3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fGS2lEPTB;NT6zPFI5PiEQvF2=	MoXxV2FPT0WU
GR-ST	NX;oSmZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlj2TWM2OD13LkO4N\|IzKM7:TR?=	M1nQVXNCVkeHUh?=
P12-ICHIKAWA	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3iNGxbUUN3ME21MlQxOSEQvF2=	NXP0c5FPW0GQR1XS
NCI-H1092	NGm1cYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVKzbnI3UUN3ME21MlQyOTR6IN88US=>	MlnXV2FPT0WU
SCC-4	M{PSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\MUFVVUUN3ME21MlQyOzV3IN88US=>	M1nL[HNCVkeHUh?=
TE-6	NWHjeI56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHZVWtKSzVyPUWuOFE5OTZizszN	NWP1d2pHW0GQR1XS
DOHH-2	NF32bWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnL4TWM2OD13LkSyNlQ5KM7:TR?=	MYDTRW5ITVJ?
SW684	M1n5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrTTWM2OD13Lk[2N\|g2KM7:TR?=	NWqxUmpqW0GQR1XS
CP50-MEL-B	M2Luc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTGTWM2OD13Lk[4Olg1KM7:TR?=	MnTFV2FPT0WU
UM-UC-3	NGLaUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rJe2lEPTB;NT63NlI{OSEQvF2=	NXnlRnBMW0GQR1XS
LC-2-ad	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LFemlEPTB;NT63PFI2OSEQvF2=	NWm5dmR6W0GQR1XS
PC-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHaNGhKSzVyPUWuPVE3OTVizszN	M1vFeHNCVkeHUh?=
CAN	M2\rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHxbWtKSzVyPUWuPVI5OiEQvF2=	M1nqXHNCVkeHUh?=
ESS-1	M{jkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTVwOUe4Olkh\|ryP	NF3ZTGxUSU6JRWK=
ATN-1	M4jwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHSTWM2OD14LkC1OVY5KM7:TR?=	NGDoelNUSU6JRWK=
BxPC-3	NGno[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTZwMEiyNVkh\|ryP	M2HTeHNCVkeHUh?=
KYSE-150	NGHT[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTZwMUK0O\|Yh\|ryP	Ml\GV2FPT0WU
RPMI-8866	NIe2[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTZwMUmxOlMh\|ryP	NECyXXRUSU6JRWK=
SW780	NE\HOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3SS2dKSzVyPU[uNlA1OiEQvF2=	NV;LOo1PW0GQR1XS
A388	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TUWGlEPTB;Nj6yN\|EyPSEQvF2=	MkTCV2FPT0WU
NCI-H1437	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4m4T2lEPTB;Nj6yOFA4OyEQvF2=	M{WxXnNCVkeHUh?=
NCI-H1755	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDJTWM2OD14LkO2OlEzKM7:TR?=	NYTnVI84W0GQR1XS
LS-123	NH[xRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrBTWM2OD14LkSwOVIyKM7:TR?=	MXHTRW5ITVJ?
CaR-1	NYrJW45KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmqyTWM2OD14LkS2N\|c{KM7:TR?=	MlvDV2FPT0WU
RT-112	M3\WWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7HOpZUUUN3ME22MlYxOzN6IN88US=>	MnToV2FPT0WU
CGT	NGrMN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTZwN{O2PFEh\|ryP	NUjnUWlDW0GQR1XS
SW626	NWLRfXVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTZwN{O5OFYh\|ryP	NXjDUFVSW0GQR1XS
AsPC-1	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;HOIl4UUN3ME22Mlc1PTB5IN88US=>	M{THb3NCVkeHUh?=
SBC-5	NFm4OIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnTSItKSzVyPU[uPVczQTdizszN	NVPLNIM4W0GQR1XS
SF539	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTZwOUmzN\|Mh\|ryP	MYTTRW5ITVJ?
TI-73	M1LBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\ydnFEUUN3ME23MlA3Ojh3IN88US=>	MVnTRW5ITVJ?
MHH-ES-1	NF;FWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmThTWM2OD15LkC3O\|YzKM7:TR?=	MmjnV2FPT0WU
KYSE-510	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\PfGlEPTB;Nz6wPFQ{OiEQvF2=	M1HDeXNCVkeHUh?=
EW-1	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\KNIMzUUN3ME23MlM3QTl4IN88US=>	MYHTRW5ITVJ?
SK-OV-3	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnNO4l7UUN3ME23MlM6PDN{IN88US=>	NXXKblVKW0GQR1XS
MC-IXC	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j4UWlEPTB;Nz60NVk4OiEQvF2=	MX\TRW5ITVJ?
HSC-2	M{\Ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLJOHdKSzVyPUeuOFI4ODVizszN	NH7xbGZUSU6JRWK=
NCI-H2342	NHXqNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfSOplKSzVyPUeuOVE1QSEQvF2=	MY\TRW5ITVJ?
NCI-H1792	M1Hob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fpV2lEPTB;Nz61NVcyOSEQvF2=	MoLIV2FPT0WU
HT-1376	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TJdWlEPTB;Nz64O\|c4QCEQvF2=	Mmr2V2FPT0WU
EW-13	M{f6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HZ[mlEPTB;Nz64PVk4PyEQvF2=	MW\TRW5ITVJ?
no-11	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTdwOUCxO\|Qh\|ryP	MYrTRW5ITVJ?
Daoy	NX:3Z2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTdwOUSzNlEh\|ryP	NF3NNo9USU6JRWK=
COLO-800	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3H2b2lEPTB;OD6wOFE3OiEQvF2=	NYXQcnpFW0GQR1XS
GB-1	NHf3VmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LtcmlEPTB;OD6wOlU3PSEQvF2=	MYnTRW5ITVJ?
SJRH30	NXzQUXFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTlUJNKSzVyPUiuNVU5PzhizszN	MnruV2FPT0WU
NCI-H2291	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvjTWM2OD16LkK5NVg4KM7:TR?=	MV\TRW5ITVJ?
J82	M2C0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPVXJJKSzVyPUiuNlk1QTFizszN	M1\BUnNCVkeHUh?=
NCI-H596	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRThwM{G0OVMh\|ryP	NELiZppUSU6JRWK=
RERF-LC-MS	NEfmS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHROpFKSzVyPUiuN\|Q5PTZizszN	NWTwW\|I5W0GQR1XS
RH-18	M{nxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW[1bmpjUUN3ME24MlM2ODR4IN88US=>	NXWxfFNWW0GQR1XS
SW48	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRThwNUm0OVMh\|ryP	NV\0WZdkW0GQR1XS
RD	NGS2bohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HFOmlEPTB;OD61PVM6OSEQvF2=	Mn3NV2FPT0WU
MS-1	M1vwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRThwNkGzPFch\|ryP	MXvTRW5ITVJ?
ES6	NEPuUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYX2dVlSUUN3ME24Mlc{OTF7IN88US=>	M{TwO3NCVkeHUh?=
TE-12	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFK4Z5hKSzVyPUiuO\|c2ODVizszN	M1LCSXNCVkeHUh?=
DBTRG-05MG	M1XQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17ZNWlEPTB;OD65NVIyPyEQvF2=	NW\oOJhKW0GQR1XS
KINGS-1	NYfmcXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPtfJZKSzVyPUiuPVI6OzhizszN	MXTTRW5ITVJ?
HLE	NX\IUGtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPvdIFKSzVyPUiuPVM4QDVizszN	MVHTRW5ITVJ?
MHH-NB-11	M{LvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M364dmlEPTB;OT6wNVg{QSEQvF2=	NXvTSHZCW0GQR1XS
U-87-MG	NH;FcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHLcWZEUUN3ME25MlI1OzJzIN88US=>	MU\TRW5ITVJ?
MN-60	NHS2WoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTlwMkS1OFIh\|ryP	NVGwPFFqW0GQR1XS
SAS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjmTWM2OD17LkK1OVgyKM7:TR?=	NHzhW3JUSU6JRWK=
NCI-H446	NGjqemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHPTWM2OD17LkO2NUDPxE1?	NWrkdllUW0GQR1XS
C-33-A	NYH6VVU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3JTWM2OD17LkSzPVg5KM7:TR?=	Mm\pV2FPT0WU
RXF393	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTlwNEewNFIh\|ryP	M2i0XHNCVkeHUh?=
CGTH-W-1	NH\rPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvOdIxKSzVyPUmuOFk{QDRizszN	MmjDV2FPT0WU
RCM-1	M{O2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDlPWUzUUN3ME25MlY{QDBzIN88US=>	NFOyXGNUSU6JRWK=
SN12C	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnOTWM2OD17Lk[1N\|M5KM7:TR?=	NIr3bpNUSU6JRWK=
KLE	NH[wbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TpemlEPTB;OT63NFAxQSEQvF2=	NFW0[3pUSU6JRWK=
EFO-21	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jZXmlEPTB;OT63O\|M5OiEQvF2=	M4XXfnNCVkeHUh?=
KYSE-70	M3vZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrDNmdKSzVyPUmuPFgxOTFizszN	NFTN[\|hUSU6JRWK=
D-247MG	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\UTWM2OD1zMD6wOVY5KM7:TR?=	MmrBV2FPT0WU
MPP-89	NUfweGVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjUO\|E1UUN3ME2xNE4xQTR4IN88US=>	MorZV2FPT0WU
RVH-421	NELydYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfmUXZbUUN3ME2xNE4yPTB3IN88US=>	MX7TRW5ITVJ?
NCI-H460	NUTHXJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHTWllKSzVyPUGwMlI5ODZizszN	M{L0WnNCVkeHUh?=
NOMO-1	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jTdGlEPTB;MUCuN\|U{OiEQvF2=	MVfTRW5ITVJ?
DEL	NFPHRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LQPWlEPTB;MUCuN\|c6PCEQvF2=	NGXicndUSU6JRWK=
HT55	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYT6RmQ{UUN3ME2xNE43OjB3IN88US=>	M1zWVXNCVkeHUh?=
MC116	NFTDNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzvc\|NKSzVyPUGwMlY3PTVizszN	M13XRXNCVkeHUh?=
BB30-HNC	NWr4R2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\jRmlEPTB;MUCuOlY6KM7:TR?=	M3zSN3NCVkeHUh?=
DJM-1	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTFyLk[5OFkh\|ryP	MV;TRW5ITVJ?
ZR-75-30	M2rw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrw[5pbUUN3ME2xNE46PDRzIN88US=>	MlrFV2FPT0WU
U-118-MG	NF\vTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW0TWM2OD1zMD65PFk3KM7:TR?=	NIjvZXFUSU6JRWK=
MSTO-211H	NFPafGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fubWlEPTB;MUGuNFcyPiEQvF2=	NFHMUG5USU6JRWK=
SW837	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\wTWM2OD1zMT6wPVQ6KM7:TR?=	NGniZplUSU6JRWK=
HuCCT1	NHHxcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGqwcpFKSzVyPUGxMlEzQDFizszN	NHv3eZJUSU6JRWK=
RCC10RGB	NUL1UnV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTFzLkGzOUDPxE1?	MXnTRW5ITVJ?
NMC-G1	NYPxTYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf0TWM2OD1zMT6xOFk{KM7:TR?=	NFnpWVFUSU6JRWK=
NCI-H650	NHTIfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PtT2lEPTB;MUGuN\|c6PCEQvF2=	MUnTRW5ITVJ?
HEC-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTFzLkSzNlgh\|ryP	NFv6d5dUSU6JRWK=
DU-4475	NELpUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M362VGlEPTB;MUGuO\|M6OyEQvF2=	MVvTRW5ITVJ?
DSH1	MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjHRmNYUUN3ME2xNU44PjB4IN88US=>	MWTTRW5ITVJ?
HCC1569	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{X3Z2lEPTB;MUGuO\|Y4QCEQvF2=	Mlz3V2FPT0WU
HCC1187	NH;JT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M32wRmlEPTB;MUGuPFU5QCEQvF2=	M1HFNXNCVkeHUh?=
EW-11	MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nNSGlEPTB;MUGuPVQ4PCEQvF2=	MmTGV2FPT0WU
LB2518-MEL	NGTRe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPxTWM2OD1zMj6wOVkh\|ryP	MVzTRW5ITVJ?
KALS-1	NXznXohGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfNNFBKSzVyPUGyMlg2PTNizszN	Mn\TV2FPT0WU
8505C	NUH4NmJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUm3VIZvUUN3ME2xNk45QDVizszN	NHfxRW1USU6JRWK=
SK-N-DZ	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF\|LkC0OVMh\|ryP	NXrnRlM5W0GQR1XS
CHP-134	NHfmeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P4cmlEPTB;MUOuNVE2QCEQvF2=	NHfjT\|RUSU6JRWK=
HCE-T	M2rEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3GTWM2OD1zMz6yN\|Y1KM7:TR?=	MXPTRW5ITVJ?
LB-831-BLC	NF\sW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1u0TmlEPTB;MUOuOlI1PiEQvF2=	NXu4WGxXW0GQR1XS
OVCAR-4	NIDaepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTF\|Lk[1NlQh\|ryP	MUfTRW5ITVJ?
SW756	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTF\|LkeyOFYh\|ryP	NITocoxUSU6JRWK=
OCUB-M	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PqdmlEPTB;MUOuPFE2PiEQvF2=	M{Xj[XNCVkeHUh?=
SW982	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTqXHBpUUN3ME2xN{45Ojd4IN88US=>	NFe3cWVUSU6JRWK=
DB	NX\VTJlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrQd4xzUUN3ME2xN{45Ozh2IN88US=>	NEPndoNUSU6JRWK=
H-EMC-SS	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXE[JRtUUN3ME2xN{46OTN7IN88US=>	M3TBcXNCVkeHUh?=
VMRC-RCZ	NF\qVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LUbmlEPTB;MUSuNFAyPSEQvF2=	MULTRW5ITVJ?
CAKI-1	M4TvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHEZldKUUN3ME2xOE4xOTN{IN88US=>	NIjyV2lUSU6JRWK=
GI-1	NF7mWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTF2LkC2OVgh\|ryP	NUW4U5RDW0GQR1XS
Ca9-22	NFu0eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPFXJd5UUN3ME2xOE43ODV2IN88US=>	Moj4V2FPT0WU
TE-5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjhflZMUUN3ME2xOE44OjB6IN88US=>	MmDaV2FPT0WU
EFO-27	NYLYXGdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnvRY1GUUN3ME2xOE44PjJ{IN88US=>	MYXTRW5ITVJ?
CAL-72	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jsNGlEPTB;MUSuO\|c5OyEQvF2=	NWjmVW1GW0GQR1XS
GP5d	M3nCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHoSZZKSzVyPUG1MlA1PzRizszN	NUKyPItSW0GQR1XS
CAS-1	NELnflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\yTWM2OD1zNT6wOlYh\|ryP	MWHTRW5ITVJ?
A2058	NGqxcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[2TWM2OD1zNT61OlM5KM7:TR?=	NEXLflZUSU6JRWK=
PANC-08-13	NHXxWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7Qb491UUN3ME2xOU43QDV7IN88US=>	M2TKNXNCVkeHUh?=
Detroit562	NWXx[3lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF3LkmxN\|kh\|ryP	NWrETZo2W0GQR1XS
PANC-10-05	M1;Dbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TaSWlEPTB;MU[uNFgzOSEQvF2=	M4f0T3NCVkeHUh?=
KOSC-2	NEnnNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfES5hKSzVyPUG2MlEyOjVizszN	MmS4V2FPT0WU
GT3TKB	NX;Fc\|VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HGcGlEPTB;MU[uNVk5OSEQvF2=	Mmf4V2FPT0WU
KM-H2	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnOwTWM2OD1zNj6zOlQ3KM7:TR?=	MmfWV2FPT0WU
LB771-HNC	NFL2WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LDTWlEPTB;MU[uOFQzOiEQvF2=	MmjFV2FPT0WU
SF268	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrSN3BKSzVyPUG2MlQ2OiEQvF2=	NEjaV5pUSU6JRWK=
OE19	NILyZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH63UllKSzVyPUG2MlUzPCEQvF2=	NXTPd3I2W0GQR1XS
MLMA	NYXtN406T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS4TWM2OD1zNj61OVcyKM7:TR?=	M3XoZXNCVkeHUh?=
MDA-MB-231	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\q[IlbUUN3ME2xOk44OTN4IN88US=>	NHzBeItUSU6JRWK=
TGW	NFfKWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;2OmhvUUN3ME2xOk45OTB{IN88US=>	NH72SWVUSU6JRWK=
MDA-MB-453	NH\sWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTF5LkCwNFMh\|ryP	MXrTRW5ITVJ?
SNU-C2B	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHK3XodKSzVyPUG3MlAzOzdizszN	MXrTRW5ITVJ?
A427	NVL1WZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnFTWM2OD1zNz6yN\|M1KM7:TR?=	NWPHTZY2W0GQR1XS
SK-MEL-2	NWjQ[ohrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zEfGlEPTB;MUeuN\|IyOyEQvF2=	Mlq1V2FPT0WU
KURAMOCHI	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TVd2lEPTB;MUeuN\|g6PyEQvF2=	MkPtV2FPT0WU
IST-MEL1	NV23SHFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzScJZjUUN3ME2xO{46OTh{IN88US=>	NVzHcFB4W0GQR1XS
NCI-H1793	NULPTm1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\UWGQzUUN3ME2xPE4yPThzIN88US=>	NILHWIhUSU6JRWK=
HCC1395	NEjCUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHpTGxKSzVyPUG4MlU3OTFizszN	MVTTRW5ITVJ?
NUGC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfzOJNKSzVyPUG4MlY2QDRizszN	NFPmb3lUSU6JRWK=
BB65-RCC	M1Lpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moi2TWM2OD1zOD62Olkh\|ryP	M2TOWnNCVkeHUh?=
RMG-I	NFHPZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu5TWM2OD1zOD63N\|gzKM7:TR?=	MWXTRW5ITVJ?
LS-513	NHLCNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{CzU2lEPTB;MUiuPVIzQCEQvF2=	NFywdXJUSU6JRWK=
MFM-223	MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\uRWlEPTB;MUmuNFcyPiEQvF2=	Moe5V2FPT0WU
NCI-H727	M4DzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TPc2lEPTB;MUmuN\|I6PSEQvF2=	Mni0V2FPT0WU
KP-4	NH3t[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jteWlEPTB;MUmuPFU{OSEQvF2=	M4\BdnNCVkeHUh?=
NB13	NGP0coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTF7Lki4N\|kh\|ryP	M1KxVXNCVkeHUh?=
UACC-893	NWXScpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Oye2lEPTB;MUmuPVc2PyEQvF2=	NF;EeZlUSU6JRWK=
HT-1197	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInVRotKSzVyPUKwMlI6PThizszN	NYnGbVR7W0GQR1XS
NCI-H2029	M2Pr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rFS2lEPTB;MkCuN\|I3PiEQvF2=	MmXpV2FPT0WU
GI-ME-N	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4m4SmlEPTB;MkCuN\|M4OyEQvF2=	Ml\DV2FPT0WU
OVCAR-3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;reGlEPTB;MkCuOVgzOiEQvF2=	NXfkWINOW0GQR1XS
HD-MY-Z	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M120cWlEPTB;MkGuN\|Y6PiEQvF2=	MkXjV2FPT0WU
NTERA-S-cl-D1	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzqTWM2OD1{MT62O\|IzKM7:TR?=	NVXKSGFEW0GQR1XS
SCH	NVLVWVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ{LkS5OkDPxE1?	NETpeFBUSU6JRWK=
KARPAS-299	M3nZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDke21KSzVyPUKzMlM5QDdizszN	NWrDUYU3W0GQR1XS
NCI-H1650	M37XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJ\|LkmyOFEh\|ryP	NYHwbXVnW0GQR1XS
ACHN	NIruVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPxSYRKSzVyPUK0MlQ3PTZizszN	MlrzV2FPT0WU
M059J	NEmwUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjCTWM2OD1{ND61OlM1KM7:TR?=	NGrPR\|VUSU6JRWK=
AM-38	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTJ3LkS4NUDPxE1?	MmDoV2FPT0WU
KG-1	NULiS3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ3LkW0PVQh\|ryP	M3;Zb3NCVkeHUh?=
COLO-824	NFTGW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzt[mFQUUN3ME2yOU42PTl7IN88US=>	MXfTRW5ITVJ?
NCI-H1155	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HCT2lEPTB;MkWuOVg1PyEQvF2=	NET6R2lUSU6JRWK=
NCI-H441	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVH5RmR{UUN3ME2yOU44PDZ3IN88US=>	NHrXOFdUSU6JRWK=
J-RT3-T3-5	M3P6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LMWGlEPTB;Mk[uN\|AzPyEQvF2=	MVvTRW5ITVJ?
JEG-3	M4\DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTJ4Lk[4NFUh\|ryP	MkWzV2FPT0WU
RKO	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDzU4FpUUN3ME2yOk44PjN{IN88US=>	NITYcoJUSU6JRWK=
CAL-85-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfVZ4VtUUN3ME2yO{4zOTF6IN88US=>	MX\TRW5ITVJ?
CAL-120	NWXKXnRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTmV3NKSzVyPUK3MlY6OTRizszN	M3H3cXNCVkeHUh?=
NCI-H2452	NGHZRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7OSZZKSzVyPUK3Mlc4OTZizszN	M4PNe3NCVkeHUh?=
NCI-H1395	NFjsSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LkcWlEPTB;MkeuO\|g{OyEQvF2=	MmPIV2FPT0WU
KYSE-450	NGjOOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJ5Lkm4OlIh\|ryP	MlfJV2FPT0WU
S-117	M4P2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PlU2lEPTB;MkmuN\|g2PyEQvF2=	NIHLepBUSU6JRWK=
SW13	NXTZd\|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmn1TWM2OD1{OT64OVE6KM7:TR?=	NYK4coZkW0GQR1XS
ES3	M{TBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\MU2pDUUN3ME2zNE4{PzN\|IN88US=>	NYLDbplpW0GQR1XS
HCT-116	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTNyLkW1OVQh\|ryP	NGnJR\|NUSU6JRWK=
NCI-H1693	NUHsRY06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTrTWM2OD1\|MD61PVQzKM7:TR?=	MXrTRW5ITVJ?
VM-CUB-1	M{XYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHVTWM2OD1\|MD62OFE{KM7:TR?=	M4HrVHNCVkeHUh?=
NCI-H2170	M2O2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmmzTWM2OD1\|MT61O\|g1KM7:TR?=	M{DxfHNCVkeHUh?=
ALL-PO	M3jOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M131fWlEPTB;M{GuPFQzQCEQvF2=	Ml7WV2FPT0WU
NCI-H661	NHjLSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGn2XZZKSzVyPUOyMlA3OjNizszN	NXW1Nm1{W0GQR1XS
NCI-H2347	NWjC[HJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTN{LkS4N\|ch\|ryP	M2jkdHNCVkeHUh?=
FTC-133	M3zPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTN{LkewOkDPxE1?	NIC0PWlUSU6JRWK=
COLO-829	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7xXVY4UUN3ME2zN{4{PDZ5IN88US=>	M4X2bHNCVkeHUh?=
GOTO	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[zdGxqUUN3ME2zN{42OjV6IN88US=>	NF\TXVZUSU6JRWK=
YAPC	NX\hdHVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H0NmlEPTB;M{OuPFE2QSEQvF2=	NVzJS2NOW0GQR1XS
LCLC-103H	MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTN2LkG2NlQh\|ryP	MVnTRW5ITVJ?
SiHa	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITmcIlKSzVyPUO0MlM5OTdizszN	NGe4WlFUSU6JRWK=
LK-2	NF\Jb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DFVWlEPTB;M{SuOVcxQCEQvF2=	NVfYcm9bW0GQR1XS
KP-N-YS	M3rxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnGxTWM2OD1\|ND63NlAzKM7:TR?=	NFf1O4pUSU6JRWK=
NCI-SNU-1	NWLJeZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjtTWM2OD1\|NT6xO\|kh\|ryP	NUTFWmI6W0GQR1XS
KNS-81-FD	NULueFdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTN3Lk[2N{DPxE1?	NEG2ZWdUSU6JRWK=
SCC-9	M4fsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHCTo5PUUN3ME2zOk44OTR4IN88US=>	M{fiSXNCVkeHUh?=
SH-4	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe1XIZrUUN3ME2zOk44OyEQvF2=	MV;TRW5ITVJ?
HCC-1954	NVfDTFRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;HXZlKSzVyPUO3MlI4OjlizszN	M1rHfHNCVkeHUh?=
BALL-1	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILiV4FKSzVyPUO3MlU{OTZizszN	MnOxV2FPT0WU
BE-13	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7qcGUxUUN3ME2zO{44ODF6IN88US=>	MUHTRW5ITVJ?
COLO-678	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLiTWM2OD1\|Nz65OFM4KM7:TR?=	MnXmV2FPT0WU
SK-MEL-3	M{nKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEmwcJBKSzVyPUO4MlI{QTdizszN	MVjTRW5ITVJ?
OAW-28	NWfKXG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7JfodKSzVyPUO4MlY{QSEQvF2=	M4\nbnNCVkeHUh?=
CAMA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfpTYFKSzVyPUO4Mlk3QTFizszN	NFriOZFUSU6JRWK=
C2BBe1	NIrPVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1y5bWlEPTB;M{muPFE5KM7:TR?=	MmT0V2FPT0WU
A3-KAW	NFm0PG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjZTWM2OD12MD6zOlYyKM7:TR?=	NYrqSldoW0GQR1XS
SK-MEL-24	M1HSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HTVWlEPTB;NECuOVk{OSEQvF2=	MVvTRW5ITVJ?
KYSE-140	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;NTWM2OD12MD63NVY2KM7:TR?=	NGDo[2FUSU6JRWK=
MOLT-16	M3fKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTRzLkG1N\|Yh\|ryP	NHz3NZdUSU6JRWK=
CFPAC-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTR{LkWyNVEh\|ryP	Mnr3V2FPT0WU
NB14	NGHPdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrUe4JKSzVyPUSyMlcxOjdizszN	NV;YW2xVW0GQR1XS
COLO-792	M{O1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTR{Lki5OlEh\|ryP	M1uyeHNCVkeHUh?=
RH-1	NFi5cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\0U5d1UUN3ME20N{41QDN4IN88US=>	MWnTRW5ITVJ?
NCI-H522	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrzNnZsUUN3ME20OE4{PTZ6IN88US=>	MVvTRW5ITVJ?
Ca-Ski	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTRfJpKUUN3ME20OE45OTF2IN88US=>	MoHFV2FPT0WU
KGN	M1jCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjNTWM2OD12OD6zNFY{KM7:TR?=	MmC2V2FPT0WU
UACC-62	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorXTWM2OD12OD60NFczKM7:TR?=	NGn5TnBUSU6JRWK=
NCI-H358	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LKSGlEPTB;NEmuN\|AyQCEQvF2=	MmXaV2FPT0WU
LS-411N	NFLmc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTR7LkOxNVgh\|ryP	MlTTV2FPT0WU
IST-MES1	NUT2cIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGKyXZlKSzVyPUS5MlU3OjVizszN	M4OzPXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)